var data={"title":"Cosyntropin (tetracosactide): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Cosyntropin (tetracosactide): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5949?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=cosyntropin-tetracosactide-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Cosyntropin (tetracosactide): Pediatric drug information&quot;</a> and <a href=\"topic.htm?path=cosyntropin-tetracosactide-patient-drug-information\" class=\"drug drug_patient\">see &quot;Cosyntropin (tetracosactide): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154800\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Cortrosyn</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154801\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Cortrosyn;</li>\n      <li>Synacthen Depot</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154832\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Corticosteroid, Systemic;</li>\n      <li>\n        Diagnostic Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154802\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diagnostic use: Screening of adrenocortical insufficiency: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cosyntropin <b>powder</b> for injection (IM, IV) <b>or</b> cosyntropin <b>solution</b> for injection (IV only [manufacturer labeling does not recommend IM administration of solution for injection]):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Conventional dose:</i> 0.25 mg; <b>Note:</b> Doses in the range of 0.25 to 0.75 mg have been used in clinical studies; however, maximal response is seen with 0.25 mg dose. When greater cortisol stimulation is needed, an IV infusion may be used: 0.25 mg administered at 0.04 mg/hour over 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Low-dose protocol (off-label dose):</i> 1 mcg (Abdu 1999); <b>Note:</b> The use of the low-dose protocol has been advocated by some clinicians, particularly in mild or secondary adrenal insufficiency. The low-dose protocol is not recommended in critically-ill patients (Marik 2008). The Endocrine Society practice guideline recommends the conventional dose (ie, 0.25 mg) for diagnosing primary adrenal insufficiency and suggests that the low-dose be used only when cosyntropin is in short supply (ES [Bornstein 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Synacthen Depot [Canadian product]: IM: 1 mg administered as a single dose or once daily for 3 or 4 days (depending on method of testing; refer to manufacturer labeling for detailed information). <b>Note:</b> For patients with severe adrenal insufficiency, some clinicians administer dexamethasone on days that Synacthen Depot is administered to provide steroid coverage.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Therapeutic use:</b> Synacthen Depot [Canadian product]: IM (<b>Note:</b> Titrate to lowest effective dose at the longest effective dosing interval): Initial for acute treatment: 1 mg daily for 3 days; maintenance dose is individualized: 0.5 to 1 mg every 2 to 3 days or twice weekly or 2 mg once weekly or less frequently</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Transferring from corticosteroids:</b> Synacthen Depot [Canadian product]: IM: Initial: 1 mg daily; gradually reduce steroid by 25% of original dose on successive days. Upon withdrawal from steroid adjust Synacthen  Depot dose as needed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Transferring from animal-derived ACTH:</b> Synacthen Depot [Canadian product]: IM: Conversion varies depending on product previously used. Manufacturer suggests that patients previously receiving ACTH gel 40 units daily should receive Synacthen Depot 0.5 mg every other day; adjust dose based on response, preferably by extending the dosing interval.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154818\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=cosyntropin-tetracosactide-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Cosyntropin (tetracosactide): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Diagnostic use: Screening of adrenocortical insufficiency: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cosyntropin <b>powder</b> for injection (IM, IV) <b>or</b> cosyntropin <b>solution</b> for injection (IV only [manufacturer labeling does not recommend IM administration of solution for injection]):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children &le;2 years: 0.125 mg </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children &gt;2 years: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Synacthen Depot [Canadian product]: IM: Children &gt;3 years: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Therapeutic use:</b> Synacthen Depot [Canadian product]: IM: <b>Note:</b> Titrate to lowest effective dose at the longest effective dosing interval.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children 3 to 6 years: Initial: 0.25 to 0.5 mg daily; maintenance: 0.25 to 0.5 mg every 2 to 8 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children 7 to 15 years: Initial: 0.25 to 1 mg daily; maintenance: 0.25 to 1 mg every 2 to 8 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children &ge;16 years: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Transferring from corticosteroids:</b> Synacthen Depot [Canadian product]: IM: Children &gt;3 years: Refer to adult dosing. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Transferring from animal-derived ACTH:</b> Synacthen Depot [Canadian product]: IM: Children &gt;3 years: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154803\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15043625\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in manufacturer&rsquo;s labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15043626\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in manufacturer&rsquo;s labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154785\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cortrosyn: 0.25 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.25 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.25 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154772\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15043640\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, suspension:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Synacthen Depot: 1 mg/mL (1 mL) [contains benzyl alcohol]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154788\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: May administer by IV injection over 2 minutes or as an IV infusion over 4 to 8 hours. Synacthen Depot [Canadian product] should <b>not</b> be administered intravenously.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM: May administer IM (reconstituted powder for injection only); cosyntropin injection <b>solution</b> is not recommended for IM administration (manufacturer recommendation).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Synacthen Depot [Canadian product]: Shake ampul until uniform appearance; administer by IM injection in the buttocks. Self-administration by patient is not recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154787\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diagnostic use: Screening of adrenocortical insufficiency: </b>Diagnostic agent used to screen patients presumed to have adrenocortical insufficiency</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Synacthen Depot [Canadian product]: Additional indications: Treatment of various disease states (eg, collagen, dermatologic, endocrine, ocular, hemolytic). Consult manufacturer labeling for detailed list.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154837\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Cortrosyn may be confused with colchicine, corticorelin, corticotropin, Cotazym</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Cosyntropin may be confused with corticorelin, corticotropin</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154779\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined. Adverse events associated with other corticosteroids may be observed when Synacthen Depot (Canadian product) is used for therapeutic purposes. Refer to corticosteroid monographs for comprehensive lists.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Cardiovascular: Bradycardia, hypertension, peripheral edema, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Skin rash, urticaria at injection site (with erythema)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing and/or case reports: Adrenal hemorrhage (Synacthen Depot)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154791\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to cosyntropin or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Synacthen Depot [Canadian product]: Additional contraindications: Treatment of asthma or other allergic conditions (increased risk of anaphylactic reactions); use in premature babies and neonates &lt;1 month; acute psychosis; untreated bacterial, fungal, and viral infections; active or latent peptic ulcer; refractory heart failure; Cushing&rsquo;s syndrome; treatment of primary adrenocortical insufficiency; adrenogenital syndrome</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154776\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Corticotropin allergy: Cortrosyn: Use with caution in patients with a history of allergic reactions to corticotropin or preexisting allergic disease. Synacthen Depot [Canadian product] is contraindicated in patients with allergic conditions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity reactions: Synacthen Depot [Canadian product]: Hypersensitivity reactions (including severe reactions) may occur particularly in patients with asthma or other allergies and often within 30 minutes of administration; monitor for hypersensitivity for ~1 hour after administration. Prolonged use may increase the risk of allergic reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiovascular disease: Synacthen Depot [Canadian product]: Use caution in patients with hypertension or thromboembolic disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Gastrointestinal disease: Synacthen Depot [Canadian product]: Use caution in patients with nonspecific ulcerative colitis, diverticulitis, or recent intestinal anastomosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic disease: Synacthen Depot [Canadian product]: Enhanced effects may be observed in patients with cirrhosis of the liver.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Infections: Synacthen Depot [Canadian product]: Use caution in patients with acute or chronic infections (especially varicella or vaccinia) or exanthematous and fungal diseases. Use with caution in patients with latent tuberculosis; treatment may reactivate latent tuberculosis. Rule out amebiasis prior to initiating therapy; may activate latent amebiasis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Myasthenia gravis: Synacthen Depot [Canadian product]: Use caution in patients with myasthenia gravis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Ocular disease: Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged use. Not recommended for the treatment of optic neuritis; may increase frequency of new episodes. Consider routine eye exams in chronic users.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Osteoporosis: Synacthen Depot [Canadian product]: Use caution in patients with osteoporosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Psychiatric disturbances: Corticosteroid use may cause psychiatric disturbances, including depression, euphoria, insomnia, mood swings, and personality changes. Preexisting psychiatric conditions may be exacerbated by corticosteroid use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal disease: Synacthen Depot [Canadian product]: Use caution in patients with renal insufficiency.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Thyroid disease: Synacthen Depot [Canadian product]: Enhanced effects may be observed with hypothyroidism.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage forms specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Synacthen Depot [Canadian product]: Contains benzyl alcohol; avoid use in infants and children &lt;3 years of age; contraindicated in neonates. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Immunizations: Synacthen Depot [Canadian product]: Live vaccines should not be given concurrently.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Surgery/trauma: Synacthen Depot [Canadian product]: Augmentation or resumption of therapy may be necessary in patients undergoing surgery or subjected to trauma either during or within 1 year of therapy discontinuation; adjunctive rapid acting corticosteroids may be necessary during periods of stress.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299097\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6219534\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9298&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">ClonazePAM: Cosyntropin may enhance the hepatotoxic effect of ClonazePAM. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DiazePAM: Cosyntropin may enhance the hepatotoxic effect of DiazePAM. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitrazepam: Cosyntropin may enhance the hepatotoxic effect of Nitrazepam. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PHENobarbital: Cosyntropin may enhance the hepatotoxic effect of PHENobarbital. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: Cosyntropin may enhance the hepatotoxic effect of Phenytoin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Primidone: Cosyntropin may enhance the hepatotoxic effect of Primidone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valproate Products: Cosyntropin may enhance the hepatotoxic effect of Valproate Products.  Management: Avoid concomitant use of Synacthen Depot (dosage form available in Canada) with valproic acid.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154782\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13447516\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted with cosyntropin; adverse events have been observed with corticosteroids in animal reproduction studies. Some studies have shown an association between first trimester systemic corticosteroid use and oral clefts (Park-Wyllie 2000; Pradat 2003). Systemic corticosteroids may also influence fetal growth (decreased birth weight); however, information is conflicting (Lunghi 2010). When systemic corticosteroids are needed in pregnancy, it is generally recommended to use the lowest effective dose for the shortest duration of time, avoiding high doses during the first trimester (Leachman 2006; Lunghi 2010; Makol 2011; &Oslash;stensen 2009). Cosyntropin is the recommended test to diagnose primary adrenal insufficiency during pregnancy. Pregnancy may alter cortisol levels, and higher concentrations are used to interpret the results based on trimester (Bornstein 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21279060\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if cosyntropin is excreted into breast milk. The manufacturer recommends that caution be exercised when administering cosyntropin to nursing women. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15043638\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Synacthen Depot [Canadian product]: Observe patient for ~1 hour after administration for signs/symptoms of hypersensitivity; for diagnosis of adrenocortical Insufficiency measure plasma cortisol prior to and 4-6 hours after injection; with prolonged use monitor blood pressure, weight, urinalysis, glucose, electrolytes, signs and symptoms of infection, cataract formation, intraocular pressure, bone mass density and growth in children, ECG (in children)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154786\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Normal baseline cortisol &gt;5 mcg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Response following a 0.25 mg dose: Peak cortisol levels &lt;18 mcg/dL (assay dependent) at 30 or 60 minutes indicate adrenal insufficiency (ES [Bornstein 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Synacthen Depot [Canadian product]: 5-hour test: Plasma cortisol levels double in first hour then increase more gradually; normal values at 5 hours: 37-66 mcg/dL; 3-day test (control phase days 1 and 2, dosing on days 3-5): compared to control phase, urinary cortisol excretion at least doubles on day 3 and further increases on days 4 and 5</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154775\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Stimulates the adrenal cortex to secrete adrenal steroids (including hydrocortisone, cortisone), androgenic substances, and a small amount of aldosterone</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154790\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: IM, IV: Within 5 minutes increases in plasma cortisol concentrations are observed in healthy individuals</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Maximum effect: IM, IV: 45-60 minutes peak plasma cortisol concentration </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration of action: Synacthen Depot [Canadian product]: IM: Plasma concentrations of 200-300 pg/mL maintained for 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Synacthen Depot [Canadian product]: IM: Rapid</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Synacthen Depot [Canadian product]: V<sub>d</sub>: ~43% of body weight</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Synacthen Depot [Canadian product]: 7 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: IM, IV push: ~1 hour; plasma cortisol levels rise in healthy individuals within 5 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323079\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Cortrosyn Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25 mg (1): $127.90</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Cosyntropin Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25 mg (1): $105.81</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038590\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Cortrosinta Depot (PT);</li>\n      <li>Cortrosyn (BE, HU);</li>\n      <li>Cortrosyn Depot (AE, BE, BF, BG, BH, BJ, CI, CY, CZ, EG, ET, FR, GH, GM, GN, HK, HN, HU, IQ, IR, IT, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, NL, OM, QA, SA, SC, SD, SL, SN, SY, TH, TN, TW, TZ, UG, YE, ZA, ZM, ZW);</li>\n      <li>Nuvacthen Depot (ES);</li>\n      <li>Synacthen (AR, AT, AU, BE, CH, CZ, DE, DK, GB, IE, IT, KR, LU, MT, NZ, PL, RO, RU, SE, SI);</li>\n      <li>Synacthen Deposito (CO, VE);</li>\n      <li>Synacthen Depot (AE, AT, AU, BF, BG, BH, BJ, CH, CI, CL, CY, CZ, DK, EG, ET, FI, GB, GH, GM, GN, GR, HN, HR, IL, IQ, IR, IT, JO, KE, KR, KW, LB, LR, LY, MA, ML, MR, MT, MU, MW, NE, NG, NL, NZ, OM, PL, PT, QA, SA, SC, SD, SE, SL, SN, SY, TN, TR, TZ, UG, UY, YE, ZA, ZM, ZW);</li>\n      <li>Synacthene (FR, GR, IN, VN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abdu TAM, Elhadd TA, Neary R, et al, &ldquo;Comparison of the Low Dose Short Synacthen Test (1 &mu;g), the Conventional Dose Short Synacthen Test (250 &mu;g), and the Insulin Tolerance Test for Assessment of the Hypothalamo-Pituitary-Adrenal Axis in Patients With Pituitary Disease,&rdquo; <i>J Clin Endocrinol Metab</i>, 1999, 84(3):838-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cosyntropin-tetracosactide-drug-information/abstract-text/10084558/pubmed\" target=\"_blank\" id=\"10084558\">10084558</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Annane D, Sebille V, Charpentier C, et al, &ldquo;Effect of Treatment With Low Doses of Hydrocortisone and Fludrocortisone on Mortality in Patients With Septic Shock,&rdquo; <i>JAMA</i>, 2002, 288(7):862-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cosyntropin-tetracosactide-drug-information/abstract-text/12186604/pubmed\" target=\"_blank\" id=\"12186604\">12186604</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(2):364-389. doi: 10.1210/jc.2015-1710.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cosyntropin-tetracosactide-drug-information/abstract-text/26760044/pubmed\" target=\"_blank\" id=\"26760044\">26760044</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Broide J, Soferman R, Kivity S, et al, &ldquo;Low-Dose Adrenocorticotropin Test Reveals Impaired Adrenal Function in Patients Taking Inhaled Corticosteroids,&rdquo; <i>J Clin Endocrinol Metab</i>, 1995, 80(4):1243-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cosyntropin-tetracosactide-drug-information/abstract-text/7714095/pubmed\" target=\"_blank\" id=\"7714095\">7714095</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cortrosyn (cosyntropin) [prescribing information]. Rancho Cucamonga, CA: Amphastar Pharmaceuticals, Inc; September 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leachman SA and Reed BR, &quot;The Use of Dermatologic Drugs in Pregnancy and Lactation,&quot; <i>Dermatol Clin</i>, 2006, 24(2):167-97, vi.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cosyntropin-tetracosactide-drug-information/abstract-text/16677965/pubmed\" target=\"_blank\" id=\"16677965\">16677965</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lunghi L, Pavan B, Biondi C, et al, &quot;Use of Glucocorticoids in Pregnancy,&quot;<i> Curr Pharm Des</i>, 2010, 16(32):3616-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cosyntropin-tetracosactide-drug-information/abstract-text/20977425/pubmed\" target=\"_blank\" id=\"20977425\">20977425</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Makol A, Wright K, and Amin S, &quot;Rheumatoid Arthritis and Pregnancy: Safety Considerations in Pharmacological Management,&quot; <i>Drugs</i>, 2011, 71(15):1973-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cosyntropin-tetracosactide-drug-information/abstract-text/21985166/pubmed\" target=\"_blank\" id=\"21985166\">21985166</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marik PE, &ldquo;Critical Illness-Related Corticosteroid Insufficiency,&rdquo; <i>Chest</i>, 2009, 135(1):181-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cosyntropin-tetracosactide-drug-information/abstract-text/19136406/pubmed\" target=\"_blank\" id=\"19136406\">19136406</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marik PE, Pastores SM, Annane D, et al, &ldquo;Recommendations for the Diagnosis and Management of Corticosteroid Insufficiency in Critically Ill Adult Patients: Consensus Statements From an International Task Force by the American College of Critical Care Medicine,&rdquo; <i>Crit Care Med</i>, 2008, 36(6):1937-49.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cosyntropin-tetracosactide-drug-information/abstract-text/18496365/pubmed\" target=\"_blank\" id=\"18496365\">18496365</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &Oslash;stensen M and Forger F, &quot;Management of RA Medications in Pregnant Patients,&quot; <i>Nat Rev Rheumatol</i>, 2009, 5(7):382-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cosyntropin-tetracosactide-drug-information/abstract-text/19506586/pubmed\" target=\"_blank\" id=\"19506586\">19506586</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Park-Wyllie L, Mazzotta P, Pastuszak A, et al, &quot;Birth defects After Maternal Exposure to Corticosteroids: Prospective Cohort Study and Meta-Analysis of Epidemiological Studies,&quot; <i>Teratology</i>, 2000, 62(6):385-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cosyntropin-tetracosactide-drug-information/abstract-text/11091360/pubmed\" target=\"_blank\" id=\"11091360\">11091360</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pradat P, Robert-Gnansia E, Di Tanna GL, et al, &ldquo;First Trimester Exposure to Corticosteroids and Oral Clefts,&rdquo; <i>Birth Defects Res A Clin Mol Teratol</i>, 2003, 67(12):968-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cosyntropin-tetracosactide-drug-information/abstract-text/14745915/pubmed\" target=\"_blank\" id=\"14745915\">14745915</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sprung CL, Annane D, Keh D, et al, &ldquo;Hydrocortisone Therapy for Patients With Septic Shock,&rdquo; <i>N Engl J Med</i>, 2008, 358(2):111-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cosyntropin-tetracosactide-drug-information/abstract-text/18184957/pubmed\" target=\"_blank\" id=\"18184957\">18184957</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Synacthen depot (cosyntropin) [prescribing information]. Kirkland, Quebec, Canada: Valeo Pharma Inc.; June 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thaler LM and Blevins LS, &ldquo;The Low Dose (1-&mu;g) Adrenocorticotropin Stimulation Test in the Evaluation of Patients With Suspected Central Adrenal Insufficiency,&rdquo; <i>J Clin Endocrinol Metab</i>, 1998, 83(8):2726-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cosyntropin-tetracosactide-drug-information/abstract-text/9709938/pubmed\" target=\"_blank\" id=\"9709938\">9709938</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tordjman K, Jaffe A, Grazas N, et al, &ldquo;The Role of the Low Dose (1 microgram) Adrenocorticotropin Test in the Evaluation of Patients With Pituitary Diseases,&rdquo; <i>J Clin Endocrinol Metab</i>, 1995, 80(4):1301-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cosyntropin-tetracosactide-drug-information/abstract-text/7714104/pubmed\" target=\"_blank\" id=\"7714104\">7714104</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9298 Version 126.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F154800\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F154801\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F154832\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F154802\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F154818\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F154803\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15043625\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15043626\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F154785\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F154772\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F15043640\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F154788\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F154787\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F154837\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F154779\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F154791\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F154776\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299097\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6219534\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F154782\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13447516\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F21279060\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F15043638\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F154786\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F154775\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F154790\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323079\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038590\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9298|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=cosyntropin-tetracosactide-patient-drug-information\" class=\"drug drug_patient\">Cosyntropin (tetracosactide): Patient drug information</a></li><li><a href=\"topic.htm?path=cosyntropin-tetracosactide-pediatric-drug-information\" class=\"drug drug_pediatric\">Cosyntropin (tetracosactide): Pediatric drug information</a></li></ul></div></div>","javascript":null}